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Abstract
Background and purpose: The European licence for alteplase
excludes from thrombolysis large groups of acute stroke
patients. The Polish licence was revised in 2010, but until
then many patients could receive the treatment only off-label.
Our aim was to evaluate the safety and effectiveness of intra-
venous alteplase in Polish patients not fully adhering to the
original European drug licence compared to patients treated
strictly on-label. 
Material and methods: We analysed all patient data con-
tributed to the Safe Implementation of Thrombolysis in
Stroke registry from Polish centres between October 2003
and July 2009.
Results: Off-label thrombolysis was administered in 224/946
(23.7%) patients. The most frequent deviations were: use of
intravenous antihypertensives (8.2%), age > 80 years (5.4%),
time-to-treatment > 3 hours (4.5%), oral anticoagulation
(4.2%), previous stroke with concomitant diabetes (2.1%),
and previous stroke ≤ 3 months (1.5%). We found no diffe -
rences in the ratio of symptomatic intracranial haemorrhage
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St reszc zen ie
Wstêp i cel pracy: Dostêpnoœæ leczenia trombolitycznego
w udarze niedokrwiennym mózgu jest ograniczona przez licz-
ne przeciwwskazania zapisane w europejskiej rejestracji alte-
plazy. Polska charakterystyka produktu zosta³a uaktualniona
w 2010 r., co znacz¹co rozszerzy³o mo¿liwoœci oficjalnego sto-
sowania trombolizy. Celem badania by³a ocena bezpieczeñ -
stwa i skutecznoœci alteplazy podawanej do¿ylnie w udarze
mózgu poza oficjalnymi wskazaniami lub przeciwwskaza-
niami w porównaniu z leczeniem w pe³nej zgodnoœci z euro-
pejsk¹ rejestracj¹.
Materia³ i metody: Analizie poddano wszystkie przypadki
leczenia trombolitycznego w Polsce zg³oszone do rejestru Safe
Implementation of Thrombolysis in Stroke od paŸdziernika 2003 r.
do lipca 2009 r.
Wyniki: Leczenie trombolityczne poza wskazaniami lub prze-
ciwwskazaniami rejestracyjnymi przeprowadzono u 224/946
(23,7%) chorych. Najczêstszymi odstêpstwami by³y: stoso-
wanie do¿ylnych leków przeciwnadciœnieniowych (8,2%), 
wiek powy¿ej 80 lat (5,4%), czas od zachorowania do lecze-
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(sICH) according to SITS, ECASS and NINDS definitions.
Adjusted odds for 3-month mortality were similar (OR 0.86,
95% CI: 0.51-2.41), excluding patients with previous stroke
≤ 3 months (OR 3.48, 95% CI: 0.96-12.7). Adjusted odds
for death or dependency were slightly increased (OR 1.40,
95% CI: 0.92-2.13), especially in patients aged > 80 years
(OR 2.80, 95% CI: 1.11-7.05), and with previous stroke 
≤ 3 months (OR 4.07, 95% CI: 0.97-17.1). 
Conclusions: Polish stroke patients receiving off-label throm-
bolysis tended to achieve a less favourable outcome, but they
were not at increased risk of sICH or death. Considering the
current Polish license for alteplase, it may be reasonable to
additionally stratify the risk in patients aged > 80 years or
with previous stroke ≤ 3 months.
Key words: acute stroke, thrombolysis, alteplase, off-label use,
protocol, outcome.
nia > 3 godz. (4,5%), stosowanie doustnych antykoagulan-
tów (4,2%), przebyty udar ze wspó³istniej¹c¹ cukrzyc¹ (2,1%),
przebyty udar ≤ 3 miesiêcy (1,5%). U pacjentów leczonych
poza wskazaniami lub przeciwwskazaniami nie wykazano 
zwiêkszonej czêstoœci wystêpowania objawowego krwawienia
wewn¹trz czaszkowego (sICH) wg definicji SITS, ECASS
i NINDS. Ryzyko zgonu w ci¹gu 3 miesiêcy by³o porówny-
walne (OR 0,86; 95% CI: 0,51–2,41), z wy³¹czeniem pod-
grupy z przebytym udarem ≤ 3 miesiêcy (OR 3,48; 95% CI:
0,96–12,7). Ryzyko zgonu lub niesprawnoœci by³o nieznacz-
nie zwiêkszone (OR 1,40; 95% CI: 0,92–2,13), zw³aszcza
u chorych powy¿ej 80. roku ¿ycia (OR 2,80; 95% CI: 1,11–
7,05) i po przebytym udarze mózgu ≤ 3 mie siêcy (OR 4,07;
95% CI: 0,97–17,1).
Wnioski: Polscy pacjenci otrzymuj¹cy leczenie trombolityczne
w udarze mózgu poza wskazaniami lub przeciwwskazaniami
zapisanymi w europejskiej charakterystyce alteplazy uzyskuj¹
mniej korzystny efekt leczenia. Natomiast ryzyko sICH i zgo-
nu jest porównywalne. W kontekœcie aktualnie obowi¹zuj¹cych
zapisów rejestracyjnych zasadne wydaje siê zindywidualizowa-
ne kwalifikowanie do leczenia chorych powy¿ej 80. roku ¿ycia
lub z wywiadem udaru ≤ 3 miesiêcy.
S³owa kluczowe: udar mózgu, leczenie trombolityczne, 
alteplaza, protokó³, rokowanie.
Introduction
Recombinant tissue plasminogen activator (rt-PA,
alteplase) is currently the only agent approved for throm-
bolytic therapy in acute ischaemic stroke [1-3]. Its safe-
ty and efficacy within 3 hours from stroke onset have
been proved in randomized controlled clinical trials and
confirmed by subsequent observational studies [4,5].
Unfortunately, the treatment is currently administered
to approximately 5% of all ischaemic stroke patients, and
up to 20% in thrombolysis-oriented centres [6,7]. Such
a low proportion is probably due to organizational issues
combined with numerous contraindications listed in the
European drug licence [8]. The Polish licence for
alteplase was revised in July 2010 according to the find-
ings of the ECASS-3 trial [9]. However, until this recent
amendment many patients (e.g. > 80 years of age, with
time to treatment between 3 and 4.5 hours or requiring
intravenous antihypertensives to maintain blood pressure
< 185/110 mm Hg) could receive thrombolysis only off-
label. The treatment was administered at the physician’s
discretion according to his individual judgment and pub-
lished evidence [7,10,11]. Of note, in other European
countries the original licence is still legally binding.
Treatment between 3 and 4.5 hours from the onset
of symptoms has already been proved safe and effective
[12,13]. There is also a growing body of evidence sup-
porting thrombolysis in the elderly [14-17]. Nonethe-
less, still little is known about treatment outcome in 
other groups of patients not fully adhering to the Euro-
pean drug licence. Besides, the management of pre-
existing comorbidities and stroke care in Poland is not
as effective as in Western countries [18]. Therefore,
a direct analysis of the national population is far more
accurate than the estimates extrapolated from multina-
tional studies, especially those conducted in Western
Europe and the USA.
Our aim was to evaluate the safety and effectiveness
of intravenous rt-PA in ischaemic stroke patients treat-
ed outside the European drug licence in Poland in com-
parison to patients treated strictly on-label.
Material and methods
The original European licence for alteplase in acute
ischaemic stroke was conditionally approved by the
European Medicines Agency (EMEA) in 2002. The
licence required an EU-based multicentre, multina-
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tional, academic driven, observational monitoring study
to confirm the safety and effectiveness of thrombolysis
in clinical practice [8]. As a consequence the Safe Imple-
mentation of Thrombolysis in Stroke – Monitoring
Study (SITS-MOST) was launched. It was based on
the SITS International Registry of Thrombolysis in
Stroke (SITS-ISTR) platform. SITS-MOST addressed
only the European Union member countries by 2003,
but cases of thrombolysis have been voluntarily reported
to the SITS-ISTR by many Central and Eastern Euro-
pean stroke centres. SITS-MOST concluded in 2006,
but the registry has been continuously expanding and
presently is the largest source of information about throm-
bolysis. Our study is based on all patient data contributed
by 28 Polish stroke centres between October 2003 and
July 2009. In this period the Polish licence for alteplase
was equivalent to the original European licence. The
methodology of the SITS registry has been described in
detail elsewhere [5]. The registry in Poland has been
approved by the local Ethics Committee and conducted
in accordance with the Declaration of Helsinki.
Data were acquired with the approval of the 
SITS-EAST Steering Committee and the internatio nal
coordinator, checked for internal validity and processed
for statistical analysis.
The off-label group consisted of patients fulfilling 
at least one of the following: age > 80 years, time-to-
treatment > 3 h, use of oral anticoagulants, previous stroke
within 3 months, a history of previous stroke and con-
comitant diabetes, use of unfractionated heparins (UFH),
use of intravenous antihypertensives before thrombolysis,
systolic blood pressure (SBP) > 185 mm Hg or diastolic
blood pressure (DBP) > 110 mm Hg despite antihyper-
tensive treatment, stroke severity > 25 points on the
National Institute of Health Stroke Scale (NIHSS), blood
glucose concentration < 2.8 or > 22.2 mmol/L.
Our outcome measures were 3-month mortality,
combined death or dependency (modified Rankin Scale
score [mRS] 3-6), and symptomatic intracranial haem-
orrhage (sICH). 
We distinguished between sICH definitions accord-
ing to SITS (i.e. local or remote parenchymal hae -
matoma type 2 combined with NIHSS score worsening
≥ 4 points or death within 22-36 h [22]), European
Cooperative Acute Stroke Study (ECASS) (i.e. any
haemorrhage combined with NIHSS score worsening
≥ 4 points or death within 7 days [19]) and National
Institute of Neurological Disorders and Stroke study
(NINDS) (i.e. any haemorr hage combined with NIHSS
score worsening ≥ 1 or death within 7 days [4]).
Statistical analysis
Categorical variables are presented as a ratio with the
number of valid observations. Proportions were calcu-
lated with exclusion of unknown values from the deno -
minator. Comparative analyses were planned for the off-
label patients as a whole and in subgroups. In basic
comparative statistics we used chi square test, with Yates’
correction if the expected value was < 5. Continuous
variables due to non-normal distribution are presented
as median with interquartile range (IQR), and compared
using Mann-Whitney U test. Odds are presented as
a ratio (OR) with 95% confidence interval (95% CI).
The main analysis of particular licence deviations
included all patients, also those with multiple de viations.
In the sensitivity analysis we included only patients with
isolated deviations, but calculations were not always
mathematically possible due to the limited number of
observations. We also did a separate analysis for patients
with pooled less frequent deviations (i.e. previous stroke
and diabetes, previous stroke ≤ 3 months, INR > 1.7,
blood pressure > 185/110 mm Hg, NIHSS score > 25,
blood glucose > 22.2 mmol/L). As the reference, we
always used patients fully adhering to the European
license. 
To avoid variable selection caused by spurious cor-
relations, only variables showing a relationship with the
outcome in the univariate model (defined as p < 0.10)
were included as potential predictors for constructing
multivariate models. The final multivariate model for
each outcome was identified using an interactive back-
ward stepwise approach and included only independent
(p < 0.05) outcome predictors. It was subsequently used
to verify the influence of particular variables.
All tests were two-sided, and p < 0.05 was consi -
dered statistically significant. Calculations were carried
out in STATISTICA 9.0 (StatSoft, Inc. 2010).
Results
A total of 960 patients were entered into the SITS
registry by 28 Polish centres. We excluded 14 cases due
to missing values in the critical variables. The final study
population consisted of 946 patients (43.0% females),
with median age 69 years (IQR: 59-76), and median
onset-to-treatment time of 150 min (IQR: 125-170).
Stroke severity on admission was mild (NIHSS score 
≤ 7) in 25.8%, moderate (NIHSS score 8-14) in 37.2%,
and severe (NIHSS score > 14) in 37.0% of cases.
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Median NIHSS score was 12 (IQR: 7-17). Overall 
3-month mortality reached 19.1%, while excellent (mRS
0-1) and favourable (mRS 0-2) outcomes were observed
in 36.0% and 53.3% of cases, respectively. 
Thrombolytic treatment with full adherence to the
licence was administered in 681 (72.0%) patients. We
identified 224 (23.7%) patients with at least one devia-
tion, including 30 cases with double, and 2 cases with
triple deviations. Due to missing data on licence adhe -
rence we were not able to clearly classify the remain-
 ing 41 (4.3%) patients. Academic centres tended to
admi nister off-label thrombolysis more frequently 
than regular neurological wards (116/420 vs. 108/485,
p = 0.063).
The most frequent deviations were: use of intra-
venous antihypertensives before rt-PA (8.2%), age 
> 80 years (5.4%), onset-to-treatment time > 3 h
(4.5%), use of oral anticoagulants (4.2%), including 
cases with INR > 1.7 (1.2%), a history of previous
stroke and concomitant diabetes (2.1%), and a history
of previous stroke ≤ 3 months (1.5%). Other deviations
were less frequent (Table 1).
Patients from the off-label group were significantly
older, had a higher proportion of all stroke relevant
comorbidities and pre-stroke disability, with longer
onset-to-treatment time. However, we did not observe
significant differences in stroke severity. Detailed com-
parative characteristics are shown in Table 2.
Both groups had a similar ratio of sICH according
to SITS (1.9% vs. 1.4%), ECASS (6.7% vs. 5.4%), and
NINDS (10.6% vs. 8.7%) definitions (Table 2). Mul-
tivariate analyses adjusted for independent outcome pre-
dictors also did not show increased odds for sICH in
the off-label patients (Fig. 1).
There were no differences in 3-month mortality
(21.8% vs. 18.6%) and favourable outcome (49.4% vs.
53.6%), but the off-label patients significantly less fre-
quently achieved excellent outcome (29.2% vs. 37.6%,
p = 0.041) (Table 2). Detailed distribution of mRS
scores at 3 months is presented in Fig. 2.
We did not find a significant association between 
off-label thrombolysis and the risk of death at 3 months
(OR 0.86, 95% CI: 0.51-2.41). Considering particular
deviations, we observed a trend for higher mortality in
patients with a history of previous stroke ≤ 3 months 
(OR 3.48, 95% CI: 0.96-12.7) (Fig. 3), but it was not
confirmed in the sensitivity analysis (OR 2.52, 95% CI:
0.60-11.2, p = 0.222). All analyses were adjusted for the
independent predictors (i.e. pre-stroke mRS of 0-1, dia-
betes, atrial fibrillation, congestive heart failure, oral anti-
hypertensive treatment and NIHSS score at baseline).
We also did not find a significant association between
off-label treatment and the combined risk of death and
dependency (OR 1.40, 95% CI: 0.92-2.13). The neg-
ative trend was more marked in the subgroup with the
less frequent deviations (OR 1.86, 95% CI: 0.92-3.79).
Considering particular deviations, we observed increased
odds for death or dependency in patients aged 
> 80 years (OR 2.80, 95% CI: 1.11-7.05), and a trend
in patients with a history of previous stroke ≤ 3 months
(OR 4.07, 95% CI: 0.97-17.1) (Fig. 4). In the sensi-
tivity analysis those results did not reach significance
(OR 2.57, 95% CI: 0.87-7.60, p = 0.087 and OR 3.72,
95% CI: 0.82-16.8, p = 0.087, respectively). All analy-
ses were adjusted for independent predictors (i.e. pre-
stroke mRS of 0-1, NIHSS score and glucose concen-
tration at baseline).
Discussion
This is the first multicenter national study directly
addressing the issue of off-label thrombolysis. Thanks
to the recent amendment in the Polish drug licence for
alteplase, onset-to-treatment time 3-4.5 h, age > 80 years
and intravenous antihypertensive treatment are no long -
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Particular deviations N Value
Intravenous antihypertensives 942 77 (8.2%)
Age >80 years 945 51 (5.4%)
Time to treatment > 3 h 946 43 (4.5%)
Time to treatment > 4.5 h 946 7 (0.7%)
Oral anticoagulants 943 40 (4.2%)
INR > 1.7 943 11 (1.2%)
Diabetes and previous stroke 931 20 (2.1%)
Previous stroke ≤ 3 months 942 14 (1.5%)
Treatment with UFH 943 5 (0.5%)
DBP > 110 mm Hg 916 4 (0.4%)
SBP > 185 mm Hg 916 3 (0.3%)
NIHSS score > 25 pts 922 2 (0.2%)
Glucose > 22.2 mmol/L* 902 1 (0.1%)
Table 1. Deviations from the European license between 2003 and 2009
UFH – unfractionated heparin, DBP – diastolic blood pressure, SBP – systolic blood pressure,
NIHSS – National Institutes of Health Stroke Scale
Data are presented as number of valid observations with ratio.
* There were no patients with glucose concentration < 2.8 mmol/L. 
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Off-label group On-label group p-value
n value n value
Age (years) 223 73 (62-79) 681 68 (59-75) < 0.001
Male gender 224 129 (57.6%) 681 382 (56.1%) 0.695
Body weight (kg) 223 76 (70-87) 678 77 (70-86) 0.528
Hypertension 221 181 (81.9%) 670 460 (68.6%) < 0.001
Diabetes 224 46 (20.5%) 671 99 (14.8%) 0.042
Hyperlipidaemia 200 83 (41.5%) 622 204 (32.8%) 0.025
Atrial fibrillation 222 85 (38.3%) 671 194 (28.95) 0.009
Congestive heart failure 222 53 (23.9%) 665 114 (17.1%) 0.026
Prior stroke 222 55 (24.8%) 681 53 (7.8%) < 0.001
Smoking status
current smoker 214 51 (23.8%) 656 180 (27.4%) 0.299
never smoker 209 127 (60.8%) 626 357 (57.0%) 0.343
Pre-stroke aspirin use 220 69 (31.4%) 675 194 (28.7%) 0.458
Pre-stroke LMWH 223 7 (3.1%) 681 21 (3.1%) 0.967
Antihypertensive treatment
any medication 220 165 (75.0%) 678 278 (41.0%) < 0.001
oral medication 220 126 (57.3%) 678 278 (41.0%) < 0.001
intravenous medication 224 77 (34.4%) 681 0 (0.0%) < 0.001
Pre-stroke functional status (mRS) 219 0 (0-1) 672 0 (0-0) < 0.001
excellent (mRS ≤ 1) 219 188 (85.8%) 672 632 (94.1%) < 0.001
Stroke severity (NIHSS) 208 11 (7-17) 681 12 (8-17) 0.324
mild (NIHSS ≤ 7) 208 65 (31.3%) 681 162 (23.8%) 0.031
moderate (NIHSS 8-14) 208 69 (33.2%) 681 264 (38.8%) 0.145
severe (NIHSS ≥ 15) 208 74 (35.6%) 681 255 (37.4%) 0.625
CT imaging before thrombolysis
hyperdense artery sign 204 23 (11.3%) 665 77 (11.6%) 0.905
current infarct 204 29 (14.2%) 665 123 (18.5%) 0.159
Systolic BP (mm Hg) 211 160 (144-170) 681 148 (134-160) < 0.001
Diastolic BP (mm Hg) 211 90 (80-100) 681 83 (79-90) < 0.001
Blood glucose concentration (mmol/L) 202 6.5 (5.8-7.7) 681 6.6 (5.7-7.9) 0.928
Onset-to-treatment time (min) 222 160 (130-180) 679 150 (120-170) < 0.001
time to treatment < 90 min 222 15 (6.8%) 679 51 (7.5%) 0.708
Symptomatic intracranial haemorrhage
according to SITS 208 4 (1.9%) 666 9 (1.4%) 0.790*
according to ECASS 208 14 (6.7%) 666 36 (5.4%) 0.472
according to NINDS 208 22 (10.6%) 666 58 (8.7%) 0.415
Table 2. Baseline characteristics and 3-month outcomes according to the licence adherence
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Off-label group On-label group p
n value n value
Death at 3 months 179 39 (21.8%) 571 106 (18.6%) 0.341
Functional outcome at 3 months
excellent (mRS 0-1) 178 52 (29.2%) 569 214 (37.6%) 0.041
favourable (mRS 0-2) 178 88 (49.4%) 569 305 (53.6%) 0.331
Table 2. cont.
LMWH – low-molecular-weight heparin, mRS – modified Rankin Scale, BP – blood pressure, NIHSS – National Institutes of Health Stroke Scale, CT – computed tomography, SITS – Safe
Implementation of Thrombolysis in Stroke, ECASS – European Cooperative Acute Stroke Study, NINDS – National Institute of Neurological Disorders and Stroke
Data are presented as median (IQR) or number (%).
P-value for categorical variables was calculated with χ2 test and Mann-Whitney U-test for continuous variables.
* Yates’ correction was applied.
* Adjusted for oral antihypertensive treatment
** Adjusted for atrial fibrillation, stroke severity and oral antihypertensive treatment
*** Adjusted for atrial fibrillation, diabetes, stroke severity, oral antihypertensive treatment and current infarct on CT imaging before thrombolysis
SITS – Safe Implementation of Thrombolysis in Stroke, ECASS – European Cooperative Acute Stroke Study, NINDS – National Institute of Neurological Disorders and Stroke
Fig. 1. Odds ratio (OR) for symptomatic intracranial haemorrhage (ICH) adjusted for independent predictors
0.1 0.2 0.5 1.0 2.0 5.0 10
Off-label better Off-label worse
SITS definition
ECASS definition
NINDS definition
Significant ICH according to
0.87 (0.23-3.28) 0.837
1.07 (0.55-2.11) 0.835
1.08 (0.62-1.90) 0.783
OR (95% Cl) P-value
Ratio of patients achieving excellent score (mRS 0-1) was significantly (p < 0.05) lower in the off-label group
Fig. 2. Distribution of modified Rankin scale (mRS) scores at 3 months
On-label patients
Off-label patients
0 10 20 30 40 50 60 70 80 90 100
Ratio [%]
0
15% 23% 16% 14% 10% 3% 19%
11% 18% 20% 14% 7% 8% 22%
1 2 3 4 5 Dead
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er formal contraindications. However, other contra -
indications are still binding and the European licence
has not been updated yet. Besides, even the new Polish
licence recommends individual assessment of the risk/
benefit ratio in the elderly [9]. As we mentioned before,
health care systems in different countries are not equiv-
alent. In this respect, our findings should facilitate deci-
sion making in clinical practice, particularly in Poland
and countries of Central and Eastern Europe. The study
also gives feedback to Polish stroke centres, which
despite growing experience in thrombolysis still have
much room for improvement.  
According to our data, patients not adhering to the
European license did not have an increased risk of sICH
and 3-month mortality. They tended to achieve a worse
functional outcome, especially patients > 80 years of
age. We also found a marked trend for increased risk of
death and death or dependency in patients with pre vious
stroke < 3 months. 
In a multinational analysis including 5594 patients
entered in the SITS registry by 9 Central and Eastern
Countries, 34.3% of patients received thrombolysis off-
label. There was a higher ratio of patients treated >3 h
(13.1%), but other deviations occurred with a similar
frequency. The off-label patients had a significantly high-
er ratio of sICH according to the ECASS definition
(7.1% vs. 5.3%), not confirmed in the multivariate mo -
del. They also tended to have increased risk of death at
3 months (OR 1.17, 95% CI: 0.97-1.42), especially in
patients > 80 years of age (OR 1.41, 95% CI: 0.92-
2.18). The risk of death or dependency was significant-
ly increased (OR 1.26, 95% CI: 1.08-1.48). The me -
tho dology of that study was very similar, but because 
of the large number of included patients it was possible
to calculate multivariate odds for particular deviations
using only patients with isolated deviations [20]. Those
results partially concur with our findings. However, we
observed a negative trend for patients with previous
* Previous stroke and diabetes, previous stroke ≤ 3 months, INR > 1.7, blood pressure > 185/110 mm Hg, NIHSS score > 25, blood glucose > 22.2 mmol/L.
** Model excluding baseline NIHSS score as a covariate.
NIHSS – National Institutes of Health Stroke Scale, UFH – unfractionated heparin, DBP – diastolic blood pressure, SBP – systolic blood pressure
Fig. 3. Odds ratio (OR) for 3-month mortality adjusted for independent predictors (i.e. pre-stroke modified Rankin scale score 0-1, diabetes, atrial fibrillation, 
congestive heart failure, stroke severity and oral antihypertensive treatment)
0.1 0.2 0.5 1.0 2.0 5.0 10
Off-label better Off-label worse
≥ 1 European licence deviation
≥ 1 less frequent deviation*
≥ 2 European licence deviations
Intravenous antihypertensives
Age > 80 years
Time to treatment > 3 h
Time to treatment > 4.5 h
Oral anticoagulants
INR > 1.7
Previous stroke and diabetes
Previous stroke < 3 months
Treatment with UFH
DBP > 110 mm Hg
SBP > 185 mm Hg
NIHSS score > 25 pts**
Pooled licence deviations
Particular licence deviations
0.86 (051-1.44) 0.559
1.11 (0.51-2.41) 0.795
1.35 (0.46-3.99) 0.579
1.07 (0.45-2.55) 0.874
1.42 (0.60-3.38) 0.425
0.76 (0.22-2.59) 0.660
0.44 (0.03-7.02) 0.557
0.50 (0.17-1.49) 0.210
1.11 (0.20-6.07) 0.904
0.71 (0.19-2.66) 0.254
3.48 (0.96-12.7) 0.058
1.59 (0.15-17.1) 0.702
0.56 (0.04-7.47) 0.661
0.56 (0.04-7.47) 0.661
3.47 (0.15-78.7) 0.433
OR (95% Cl) P-value
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stroke ≤ 3 months, and the age > 80 years affected mor-
tality rather than functional outcome. It may be in some
way specific to the Polish population. 
Safety and effectiveness of thrombolysis outside the
European licence has also been assessed by Meretoja 
et al. In their study, off-label alteplase was administered
to 499/985 consecutive patients admitted to a single cen-
tre in Helsinki. The most frequent deviations were age
> 80 years (16%), mild stroke (13%), use of intravenous
antihypertensives (11%), onset-to-treatment time > 3 h
(10%), blood pressure > 185/110 mm Hg (5%) and
oral anticoagulation (4%). The risk of sICH according
to the ECASS definition was not increased in the off-
label patients (OR 0.80, 95% CI: 0.43-1.48). How-
ever, they tended to have increased odds for death or
dependency (OR 1.37, 95% CI: 0.95-1.97), which was
significant in the subgroup aged > 80 years. The study
by Meretoja et al. did not examine mortality, excluded
patients with basilar artery occlusion, and considered
baseline NIHSS 0-4 a license deviation. Its multivari-
ate model included 21 variables and was not limited to
independent outcome predictors. Besides, the logistics
in Helsinki was significantly better (i.e. 34 min me dian
door-to-treatment time), and a more favourable overall
outcome was noted (8.7% on-label mortality) [21].
Despite those methodological differences, the results are
consistent with ours.
A study by Rubiera et al. assessed adherence to the
SITS-MOST protocol in 369 non-lacunar stroke
patients with a documented intracranial artery occlu-
sion, INR < 1.8 and mismatch on multiparametric
MRI if treated 3 to 6 hours from the onset of symptoms.
The non-protocol group consisted of patients treated
within 3-6 hours from onset, aged > 80 years, with
stroke severity > 25 in NIHSS, and a history of previ-
ous stroke and concomitant diabetes. There were no dif-
ferences in the rate of sICH. However, the non-proto-
col group showed a trend for increased 3-month
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* Previous stroke and diabetes, previous stroke ≤ 3 months, INR > 1.7, blood pressure > 185/110 mm Hg, NIHSS score > 25, blood glucose > 22.2 mmol/L
** Model excluding baseline NIHSS score as a covariate
NIHSS – National Institutes of Health Stroke Scale, UFH – unfractionated heparin, DBP – diastolic blood pressure, SBP – systolic blood pressure
Fig. 4. Odds ratio (OR) for death or dependency (modified Rankin scale [mRS] 3-6) adjusted for independent predictors (i.e. pre-stroke mRS 0-1, stroke severity and
glucose concentration at baseline)
0.1 0.2 0.5 1.0 2.0 5.0 10
Off-label better Off-label worse
≥ 1 European licence deviation
≥ 1 less frequent deviation*
≥ 2 European licence deviations
Intravenous antihypertensives
Age > 80 years
Time to treatment > 3 h
Time to treatment > 4.5 h
Oral anticoagulants
INR > 1.7
Previous stroke and diabetes
Previous stroke < 3 months
Treatment with UFH
DBP > 110 mmHg
SBP > 185 mmHg
NIHSS score > 25 pts**
Pooled licence deviations
Particular licence deviations
1.44 (0.92-2.13) 0.119
1.86 (0.82-3.79) 0.085
2.28 (0.69-7.53) 0.174
1.07 (0.54-2.14) 0.842
2.80 (1.11-7.05) 0.028
1.09 (0.40-2.92) 0.868
NA
1.25 (0.55-2.83) 0.592
1.86 (0.44-7.86) 0.399
0.65 (0.18-2.35) 0.509
4.07 (0.97-17.1) 0.055
1.37 (0.18-10.2) 0.758
1.01 (0.10-9.75) 0.994
1.01 (0.10-9.75) 0.994
NA
OR (95% Cl) P-value
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mortality (16.1% vs. 10.5%; p = 0.084) and a higher
ratio of death or dependency (60.4% vs. 51.7%; 
p = 0.082). After excluding patients > 80 years of age,
the proportion of unfavourable outcome was compara-
ble to the per-protocol group [11]. Despite certain
methodological differences (i.e. narrow inclusion crite-
ria, me dian NIHSS score of 17, and 124 thrombolyses 
> 3 hours from onset of symptoms) these results are
generally consistent with ours, especially in the group
> 80 years of age. 
All above-mentioned studies show that thromboly-
sis in patients not fully adhering to the SITS protocol
(European licence) may be less beneficial in compari-
son to strict on-label treatment. However, it does not
allow one to conclude that those patients do not benefit
from thrombolysis. Such evidence can be reliably pro-
vided only by the ongoing randomized controlled 
clinical trials (e.g. Third International Stroke Trial 
[IST-3], Thrombolysis in Elderly Stroke Patients in
Italy [TESPI]) [22,23]. Presently, the indirect con-
trolled comparisons of treated versus untreated patients
offer reassurance that intravenous thrombolysis is be-
neficial at least in some off-label patients (e.g. the elder-
ly or those with concomitant diabetes and prior stroke)
[17,24]. However, in other groups (i.e. NIHSS < 4 or
> 25) it appears to be dubious [25].
To our best knowledge, there is no direct eviden -
ce against using intravenous antihypertensives to main-
tain blood pressure < 185/110 mm Hg before and dur-
ing thrombolysis [26]. On the contrary, withholding
antihypertensives in patients with a history of hyper-
 tension may result in worse outcome [27]. Effective
management of blood pressure with easily reversible
intravenous agents enables optimal control of very high
blood pressure, and therefore should not be considered
a contraindication for rt-PA. Our results support this
thesis.
The evidence encourages thrombolysis in patients
> 80 years of age, but it is still discussed if we should
treat the elderly without any limits or maybe addition-
ally stratify their risk/benefit ratio. A meta-analysis of
cohort studies by Engelter et al. indicates that patients
aged > 80 years had higher 3-month mortality and 
were less likely to achieve excellent outcome (mRS ≤ 1)
[14]. In a more recent meta-analysis by Meseguer 
et al., mortality was not assessed, but the likelihood of
an un favourable outcome was also increased [15].
Unfortunately, neither analysis adjusted for other out-
come predictors. A recent study by Ford et al. shows that
the elderly from the whole SITS-ISTR population had
a higher 3-month mortality rate and reduced indepen-
dence [16]. Importantly, the risk of sICH was not
increased. This partially concurs with our findings show-
ing that age > 80 years may have a negative effect on
functional outcome. 
Intravenous thrombolysis ≤ 4.5 hours from the on -
set of symptoms or even beyond this time window 
has already been proved safe and effective [12,13,19].
In our study, patients treated > 3 hours from the on-
set did not show an increased risk of worse outcome,
which is more optimistic than in large multinational
analyses [20,28]. We hypothesize that this difference
may be due to a positively biased patient selection in 
Polish centres and a relatively small number of those
patients (n = 43). 
According to our findings, ineffective oral anticoa -
gulation probably does not increase the risk of death or
unfavourable outcome. Although concerns about sICH
have been raised by Prabhakaran et al. [29], we think
that available evidence should not discourage throm-
bolysis in patients with INR < 1.7.
The evidence on previous stroke and concomitant
diabetes, as well as previous stroke ≤ 3 months, is lim-
ited [10,20,21,24] but it does not justify withholding
treatment in those patients. In our study, patients with
a history of previous stroke ≤ 3 months may achieve
a worse outcome. This finding was slightly beyond sig-
nificance and was not confirmed in the sensitivity analy-
sis. However, the point estimates were high and it is pos-
sible that a larger sample would have yielded significant
results. Therefore, we should be careful when adminis-
tering thrombolysis to patients with a previous stroke 
≤ 3 months, at least in the Polish setting.
In our material there were only two patients with
an NIHSS score > 25 and one patient with blood glu-
cose concentration > 22.2 mmol/L. Elevated blood
glucose is associated with worse prognosis irrespec-
tively of thrombolysis [20,30], and increases the odds
for sICH after treatment [20,30,31]. Therefore, we
need to be extremely cautious considering alteplase in
patients with glucose concentration > 22.2 mmol/L.
A similar statement can be made about NIHSS score
> 25 [20,25]. 
Our study has limitations. It is based on a voluntary
registry. Therefore, it is not possible to identify how
many patients were not reported to the database and for
what reasons. We may not exclude that some of them
died early, had sICH or received rt-PA despite other
severe licence deviations. Outcomes may also be biased
because of the non-random sampling. On-label patients
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are most likely consecutive, but the off-label patients
were selected at the physician’s discretion. To minimize
the influence of confounders (e.g. worse comorbidity
state in the off-label group) we used multivariate mod-
els adjusted for all independent outcome predictors.
However, it does not eliminate their influence com-
pletely. We decided to include cases with isolated miss-
ing values to make particular estimates more precise, but
even then the number of valid cases was often low.
Therefore, the sensitivity analysis was not always possi-
ble and confidence intervals not narrow enough to draw
strong conclusions. 
Nonetheless, our findings show that in Poland, in
one in four cases, thrombolysis for acute stroke was
administered outside the drug license. The off-label
patients achieved comparable or slightly worse outcome,
but they were not at increased risk of sICH. Some con-
traindications appear definitely redundant (e.g. aggres-
sive blood pressure management with intravenous me -
dication, previous stroke with concomitant diabetes, oral
anticoagulation with INR < 1.7). Our everyday clini-
cal decision making should rely on evidence and guide-
lines. In Poland, the license for alteplase has recently
become more guideline-adherent, but in some patients
we still may have the dilemma of denying thrombolysis
only because of licence limitations. It may be reasonable
to use individual risk stratification in patients > 80 years
of age or with a history of previous stroke ≤ 3 months.
However, to make final conclusions in this matter we
still need the results of ongoing randomized trials and
other controlled studies. 
Conclusions
1. One in four cases of intravenous thrombolysis for
acute stroke in Poland was administered outside the
European drug license. 
2. The off-label patients achieved comparable or slight-
ly worse outcome, but they were not at increased risk
of sICH or death. 
3. Some contraindications appear definitely redundant
(e.g. aggressive blood pressure management with intra-
 venous medication, previous stroke with concomitant
diabetes, oral anticoagulation with INR < 1.7). 
4. Our everyday clinical decision making should rely on
evidence and guidelines. In Poland, the licence for
alteplase has recently become more guideline-adher-
ent, but in some patients we still may have the dilem-
ma of denying thrombolysis only because of licence
limitations. 
5. It may be reasonable to use individual risk stratifica-
tion in patients > 80 years of age or with a history 
of previous stroke ≤ 3 months. However, to make
final conclusions in this matter we still need the results
of ongoing randomized trials and other controlled
studies.
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Appendix 
The following centres from the SITS Poland Col-
laborative Group contributed to this study (name of the
hospital and local coordinator with the number of
included patients): 
II Klinika Neurologiczna IPiN w Warszawie 
(A. Ko bayashi – 225), SP ZZOZ w Sandomierzu 
(P. Sobo lewski – 120); Pomorskie Centrum Traumato-
logii w Gdañsku (W. Fryze – 75); Wojewódzki Zespó³
Neu ropsychiatryczny w Opolu (S. Romanowicz – 74);
Uniwersyteckie Centrum Kliniczne w Gdañsku (W. Ny -
ka – 71); Szpital Uniwersytecki nr 2 w Bydgoszczy 
(P. Lisewski – 66); CSK MSWiA w Warszawie 
(M. Do robek – 48); SP CSK SUM w Katowicach 
(G. Opala – 42); Szpital Wolski w Warszawie (A. Ku -
czyñska-Zardzewia³y – 41); Szpital Specjalistyczny
w Pile (M. Wiszniewska – 36); Szpital Specjalistyczny
w Koñ skich (M. Fudala – 30); Szpital Powiatowy
w Skar¿ysko-Kamiennej (J. Stoiñski – 23); I Klinika
Neurologiczna IPiN w Warszawie (P. Richter – 18);
Szpital Wojewódzki w Poznaniu (J. Michalska – 13);
Szpital Specjalistyczny w Koœcierzynie (A. Walczak – 9);
Szpital Specjalistyczny w Siedlcach (P. Kwiatkowski –
8); SP CSK WUM w Warszawie (H. Kwieciñski – 7);
WIM w Warszawie (J. Stêpieñ – 7); Szpital Woje-
wódzki nr 2 w Rzeszowie (M. Ziêba – 7); Wojewódz-
ki Szpital Podkarpacki w Kroœnie (R. Jucha – 6); 
Dolnoœl¹ski Szpital Specjalistyczny we Wroc³awiu 
(K. Gu rañski – 5); Wojewódzki Szpital Specjalistyczny
w Olsztynie (A. Tutaj – 5); SPPK CMKP w Warsza-
wie (W. Palasik – 4); Uniwersytecki Szpital Kliniczny
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w Bia³ymstoku (W. Drozdowski – 3); Górnoœl¹skie
Centrum Medyczne w Katowicach (A. Warsz-Wianec-
ka – 3).
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